

Sheppard Mullin Advises Cardiff Oncology, FoxWayne, Miva, And Others In Recent Deals

12.20.2021

Sheppard Mullin's Corporate practice has been busy closing a variety of deals and transactions over the past few months:

Financings

- Represented **Miva, Inc.**, a leading mid-market and enterprise ecommerce platform, in its equity investment from Boston-based growth equity firm Equality Asset Management. The Sheppard Mullin deal team was led by partners Gemma Descoteaux and John Booher and included partners David Sands, Keith Gercken and Dmitriy Chelnitsky and associate Laura Baptista. (November 18)

Mergers & Acquisitions

- Representing **FoxWayne Enterprises Acquisition Corp.** (NASDAQ: FOXWU), a special purpose acquisition company (SPAC), in its merger with Aerami Therapeutics Holdings, Inc., a biopharmaceutical company focused on developing inhaled therapies to treat severe respiratory and chronic diseases. Upon closing, which is anticipated to occur in the first quarter of 2022, the combined company will be named "Aerami Therapeutics Holdings, Inc." The Sheppard Mullin deal team is being led by partners Richard Friedman and John Hempill and includes several members of the firm's Corporate and Securities practice across several offices, including partners Stephen Cohen, Kandace Watson, Dan Yannuzzi, Michael Chan, Allison Fulton, Keith Gercken, Dmitriy Chelnitsky, Shawn Fabian, Jamie Mercer, Olivier Theard, and Leo Caseria; special counsel Sean Reid; and associates Keren Baruch, Zach Norris, Nirav Bhatt, Karl Buhler, John Crisp, Brian Egan, Susan Ingargiola, Julia Kadish, Nazia Khan, Erica Kraus, Evan Lim, David Rostowsky, Elizabeth Rowe, Theresa Thompson, Michael Weissnar, and Hannah Zelcer; and attorney Wade Riachi. (December 7)
- Represented **Sia Partners**, a leading international, independent management and AI consulting firm, in its acquisition of PPT Consulting, LLC, a privately held management and IT consulting firm that specializes in project management, business and process transformation, and organizational change management. The Sheppard Mullin deal team was led by partner Valerie Demont and associate Karl Buhler. Special assistance was provided by partners Michael Chan, Dmitriy Chelnitsky, Wynter Deagle, Niya Tang, and Dan Yannuzzi; special counsel Sean Kirby; and associates Evan Lim, Betsy Luxenberg, Deena Muzafar, and Michael Weissnar; and attorney Erin Hausladen. (December 7)

Public Offerings

- Represented **Immix Biopharma, Inc.** (Nasdaq: IMMX), a biopharmaceutical company pioneering Tissue Specific Therapeutics targeting oncology and immuno-dysregulated diseases, in its initial public offering of

\$21 million. ThinkEquity is acting as the sole book-running manager for the offering. The Sheppard Mullin deal team included partner Jeff Fessler and associates Nazia Khan and Emily Mastoloni. (December 20)

- Represented Merritt Island, Florida-based **Sidus Space Inc.** (NASDAQ:SIDU), in its \$15 million initial public offering. Sidus Space is a Space-as-a-Service satellite company. The deal team was led by partner Jeff Fessler and special counsel Sean Reid. (December 13)
- Advised **Aditxt, Inc.**, a biotech innovation company with a mission to improve the health of the immune system, in a \$17.4 million public offering. The Sheppard Mullin deal team was led by partner Richard Friedman, special counsel Sean Reid and associate and Hannah Zelcer. (December 6)
- Advised **The Benchmark Company, LLC** in connection with a public offering of Series A Cumulative Redeemable Perpetual Preferred Stock of Skylight Health Group, Inc., a healthcare services and technology company working to positively impact patient health outcomes, in a \$5.8 million public offering. The Sheppard Mullin deal team was led by partners Richard Friedman and Andrew Bond, special counsel Sean Reid, and associates Nazia Khan and Emily Mastoloni. (December 2)
- Represented **EF Hutton**, a division of Benchmark Investments, LLC, in the private sale of securities of Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, for \$30.4 million. The Sheppard Mullin team included partner Richard Friedman and associates Nazia Khan and Seth Lemings. (November 29)
- Advised **A. Davidson & Co.** as sole placement agent in Summit Bank Group, Inc.'s \$20 million private placement. Summit Bank Group is the parent company of Summit Bank, which specializes in providing high-level service to professionals and medium-sized businesses and their owners. The deal team was led by partner Josh Dean and associate Eugene Choi. (November 23)
- Represented **Cardiff Oncology**, a clinical-stage oncology company developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need, in Pfizer Inc.'s (NYSE: PFE) \$15 million equity investment in the company as part of the Pfizer Breakthrough Growth Initiative, a program focused on funding innovative science to meet patient needs. The Sheppard Mullin team was led by partner Jeff Fessler. (November 18)

Attorneys

Keren Baruch

Nirav Bhatt

Andrew J. Bond

John H. Booher

Karl Buhler

Leo Caseria

Michael Chan

Dmitriy Chelnitsky

Eugene Choi

Stephen A. Cohen

John G. Crisp

Wynter L. Deagle

Joshua A. Dean

Valérie Demont

Gemma L. Descoteaux

Brian C. Egan

Shawn D. Fabian

Jeffrey J. Fessler

Richard A. Friedman

Keith R. Gercken

Erin Hausladen

John R. Hempill

Julia K. Kadish

Nazia J. Khan

Sean J. Kirby

Erica J. Kraus

Seth A. Lemings

Evan S. Lim

Emily Mastoloni

James A. Mercer III

Zachary Norris

Sean Reid

David S. Rostowsky

David H. Sands

Niya Tang

Olivier F. Theard

Elizabeth N. Thompson

Kandace P. Watson

Michael H. Weissnar

Daniel N. Yannuzzi

Hannah Zelcer

Practice Areas

Capital Markets

Corporate

Mergers and Acquisitions

Private Equity

Industries

Healthcare

Life Sciences

Retail, Fashion & Beauty

Telecom